FDA device-related FY 1999 appropriations
This article was originally published in The Gray Sheet
Executive Summary
Report adopted 25-19 by the House Appropriations Committee June 16 sets FY 1999 funding for salaries and expenses at $148.5 mil., up 3.5% from $143.5 mil. in FY 1998. A companion measure adopted by the Senate Appropriations Committee on June 11 freezes spending at the current level. Overall, the House bill increases FDA funding for salaries and expenses in FY 1999 by 1.6%, from $857.5 mil. to $871.5 mil., not including user fees. The legislation pending in the Senate keeps appropriations at the FY 1998 level, exclusive of an $82.9 mil. provision for rental fees to the General Services Administration for FDA facilities ("The Gray Sheet" June 15, p. 30)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.